Table 1.
MDR-TB cases among the new TB patients and five MDR-TB high-risk suspect group, % (MDR number/screening number)*
| Items | New patients | MDR-TB high-risk suspect groups | Total | ||||
|---|---|---|---|---|---|---|---|
| Group 1* | Group 2* | Group 3* | Group 4* | Group 5* | |||
| Total | 2.1 (200/9530) | 10.0 (18/180) | 46.1 (149/323) | 83.8 (218/260) | 23.6 (41/174) | 28.6 (365/1277) | 8.4 (991/11744) |
| Age (years) | |||||||
| 0–29 | 2.5 (58/2305) | 21.1 (8/38) | 61.4 (54/88) | 61.4 (37/41) | 19.2 (5/26) | 100 (75/156) | 48.1 (237/2654) |
| 30–60 | 2.5 (94/3777) | 11.3 (8/71) | 48.2 (68/141) | 90.3 (130/144) | 34.9 (29/83) | 36.5 (205/580) | 11.1 (534/4796) |
| >60 | 1.4 (48/3448) | 2.8 (2/71) | 28.7 (27/94) | 68.0 (51/75) | 10.8 (7/65) | 13.6 (85/541) | 5.1 (220/4294) |
| Sex | |||||||
| Male | 2 (134/6740) | 8.5 (12/141) | 43.7 (104/238) | 83.7 (180/215) | 21.3 (30/141) | 25.8 (253/982) | 8.4 (713/8457) |
| Female | 2.4 (66/2790) | 15.4 (6/39) | 52.9 (45/85) | 84.4 (38/45) | 33.3 (11/33) | 38.0 (112/295) | 8.5 (278/3287) |
| Areas | |||||||
| Hangzhou | 2.9 (102/3501) | 14.2 (16/113) | 50.4 (125/248) | 82.1 (151/184) | 30.4 (34/112) | 32.5 (209/644) | 13.3 (637/4802) |
| Huzhou | 1.6 (17/1044) | 25.0 (1/4) | 36.4 (8/22) | 100 (37/37) | 4.3 (1/23) | 16.4 (21/128) | 6.8 (85/1258) |
| Shaoxing | 2.2 (44/1959) | 0 (0/7) | 44.4 (4/9) | 75.0 (9/12) | 0 (0/9) | 29.3 (65/222) | 5.5 (122/2218) |
| Jiaxing | 1.8 (8/433) | 2.6 (1/39) | 20.0 (2/10) | 66.7 (2/3) | 0 (0/2) | 27.9 (12/43) | 4.7 (25/530) |
| Quzhou | 0.8 (12/1584) | 0 (0/14) | 12.0 (3/25) | 58.3 (7/12) | 6.3 (1/16) | 19.8 (33/167) | 3.1 (56/1818) |
| Lishui | 1.7 (17/1009) | 0 (0/3) | 77.8 (7/9) | 100 (12/12) | 41.7 (5/12) | 34.2 (25/73) | 5.9 (66/1118) |
| Year | |||||||
| 2009 | 66.7 (2/3) | 0 (0/0) | 100 (31/31) | 100 (38/38) | 100 (10/10) | 100 (33/33) | 99.1 (114/115) |
| 2010 | 7.3 (11/150) | 44.4 (4/9) | 100 (31/31) | 96.9 (63/65) | 100 (5/5) | 89.0 (73/82) | 54.7 (187/342) |
| 2011 | 2.3 (64/2729) | 14.5 (9/62) | 30.4 (28/92) | 67.2 (39/58) | 17.5 (10/57) | 20.9 (76/363) | 6.7 (226/3361) |
| 2012 | 1.8 (60/3318) | 7.3 (3/41) | 29.1 (25/86) | 68.3 (28/41) | 11.7 (7/60) | 24.5 (99/404) | 5.6 (222/3950) |
| 2013 | 1.9 (63/3330) | 2.9 (2/68) | 41.0 (34/83) | 86.2 (50/58) | 21.4 (9/42) | 21.3 (84/395) | 6.1 (242/3976) |
*Group 1: New cases persisting sputum culture or smear positive at the end of the 2nd month after treatment; Group 2: New cases of initial treatment failure; Group 3: Re-treatment cases of treatment failure; Group 4: Cases with poor treatment compliance: patients receiving treatment and interruption and re-treatment again; Group 5: Recurrence cases. MDR: Multidrug resistant; TB: Tuberculosis.